血管内皮生长因子靶向药相关性蛋白尿发病机制和中医药治疗研究进展  

Research progress on mechanism of VEGF targeted drug-related proteinuria and treatment of traditional Chinese medicine

作　　者：章靖源 周恩超[1] ZHANG Jingyuan;ZHOU Enchao(Affiliated Hospital of Nanjing University of Chinese Medicine,Nanjing 210029,China)

机构地区：[1]南京中医药大学附属医院,江苏南京210029

出　　处：《陕西中医》2023年第5期667-669,共3页Shaanxi Journal of Traditional Chinese Medicine

基　　金：国家自然科学基金资助项目(81873270);江苏省“六大人才高峰”高层次人才项目(WSN-012);南京市科技局医疗卫生国际联合研发项目(202002051);南京中医药大学中医学优势学科三期项目(ZYX03KF076)。

摘　　要：血管内皮生长因子(VEGF)靶向药目前越来越多地应用于恶性肿瘤的临床治疗,安全有效,易耐受,但仍会产生蛋白尿等常见的不良反应。VEGF靶向药相关性蛋白尿的发病机制主要是足细胞和内皮细胞改变及血管内皮细胞功能障碍。西医对症处理多有局限性,效果不显著。中医药辨治可有效改善VEGF靶向药所致的蛋白尿,提高临床疗效,改善患者生活质量,延长生存期。今后需进一步加强中医药防治VEGF靶向药相关性蛋白尿的机制研究,开展大样本、高质量的临床试验研究,为临床提供更多的参考。VEGF targeted drugs are increasingly used in the clinical treatment of malignant tumors.They are safe,effective and easily tolerated,but they will still produce common adverse reactions such as proteinuria.The mechanism of VEGF targeted drug-related proteinuria is mainly the changes of podocytes and endothelial cells and the dysfunction of vascular endothelial cells.Western medicine has many limitations in symptomatic treatment,and the effect is not significant.TCM syndrome differentiation and treatment can effectively improve the proteinuria caused by VEGF targeted drugs,improve the clinical curative effect,improve the quality of life of patients and prolong the survival time.In the future,it is necessary to further strengthen the mechanism research of traditional Chinese medicine in the prevention and treatment of VEGF targeted drug-related proteinuria,and carry out large sample and high-quality clinical trial research,so as to provide more references for clinical practice.

关 键 词：血管内皮生长因子靶向药 蛋白尿 肾小球血栓性微血管病 微小病变性肾病 局灶节段性肾小球硬化 

分 类 号：R696.2[医药卫生—泌尿科学]